glp-1 receptor agonists in idiopathic intracranial hypertension Use of glucagon-like peptide-1 : a systematic review | The Journal of Headache and Pain Large-Scale Study Highlights Therapeutic Benefits
Description
Wyne KL, Litwin SE, Cusi K, Guyton JR
The drugs of interest included FDA-approved GLP-1RAs [26]: semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, and albiglutide
PubMed Central , Accessed 23 Apr
[DOI] [PubMed] [Google Scholar] 33.Christensen M., Bagger J.I., Vilsboll T., Knop F.K
In clinical trials, GLP-1 drugs given in higher dosages than for diabetes showed the ability to stimulate double-digit-percentage weight loss in patients
It could be significant
